Navigation Links
Isis Reports Strong Financial Results and Highlights for Second Quarter of 2009
Date:8/6/2009

, the most advanced drug in Isis' cardiovascular pipeline, is being evaluated in a broad Phase 3 program in patients who cannot adequately control their cholesterol levels with current therapies and who need new treatment options.

  • Isis and Genzyme reported positive top-line mipomersen Phase 3 data in patients with homozygous FH. The study met its primary endpoint, with a 25% reduction in LDL-C after 26 weeks of treatment, vs. 3% for placebo (p<0.001). The study also met each of its three secondary endpoints of reduction in apoB, total cholesterol and non-HDL-C.
  • Genzyme continues to refine its European strategy for mipomersen.
  • Isis and Genzyme completed enrollment in a Phase 3 study in heterozygous FH patients with coronary artery disease.

Isis' partnered pipeline continues to mature as antisense drugs that Isis' satellite companies are developing advance in clinical development.

  • Altair reported a Phase 1 study that showed AIR645 was safe and well tolerated.
  • Excaliard initiated a Phase 1 clinical study of EXC 001( )for the local treatment of fibrosis.

Isis' collaborators presented new clinical data on drugs in Isis' partnered oncology franchise at this year's American Society of Clinical Oncology (ASCO) annual meeting.

  • OncoGenex reported results of a randomized Phase 2 trial of OGX-011 in patients with advanced prostate cancer showing a median survival in patients treated with OGX-011 plus docetaxel of 23.8 months compared to 16.9 months for patients treated with docetaxel alone.
  • OncoGenex reported that OGX-427 was well tolerated as a monotherapy in a Phase 1 study and demonstrated declines in circulating tumor cells and evidence of reduction in tumor markers.
  • Eli Lilly and Company recently completed its
    '/>"/>

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22

Related medicine technology :

1. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
2. Spherix Reports Second Quarter Earnings
3. Tapestry Reports Second Quarter 2007 Results
4. Callisto Reports on Second-Quarter 2007 Milestones
5. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
6. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
7. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
8. TAXUS WOMAN Study Reports Positive Clinical Outcomes for the TAXUS(R) Drug-eluting Stent in Women
9. Biopure Reports on Meeting with the FDA
10. Peregrine Reports Data Showing Bavituximabs Potential to Shrink Prostate Tumors
11. NicOx Reports TOPIGEN to Advance TPI-1020 Into Phase 2 for COPD Following Promising Clinical Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... , July 31, 2014 AFFiRiS AG ... York results of AFF008, a Phase I clinical ... the first therapy against the protein alpha-synuclein, a promising Parkinson,s ... J. Fox Foundation for Parkinson,s Research (MJFF) supported the study ... press conference on the impact a disease-modifying therapy would have ...
(Date:7/31/2014)... , July 31, 2014 genae, a ... industries, announced today the incorporation of genae UK in ... has one of the largest medical device markets in the ... it is projected to increase by a CAGR of 6.0% until ... equal to 9.5% of GDP. Despite recessionary pressures, market growth rates ...
(Date:7/31/2014)... AUSTIN, Texas , July 31, 2014 Vermillion, ... cancers and women,s health, will hold a conference call on ... discuss results for the second quarter ended June 30, 2014. ... to the call. Vermillion,s Chairman, President and CEO ... a question and answer period. Date: Thursday, August ...
Breaking Medicine Technology:First Clinical Data of Therapeutic Parkinson's Disease Vaccine Encourages Continued Development 2First Clinical Data of Therapeutic Parkinson's Disease Vaccine Encourages Continued Development 3First Clinical Data of Therapeutic Parkinson's Disease Vaccine Encourages Continued Development 4genae Opens Offices in London 2Vermillion Sets Second Quarter 2014 Conference Call for Thursday, August 14, 2014 2
... has collaborated with the National Comprehensive Cancer Network® (NCCN®) ... ( NCCN Guidelines ™) into Elekta,s MOSAIQ® Oncology Information ... NCCN,s evidence-based clinical content directly from within the MOSAIQ ... Guidelines are widely recognized as the standard ...
... 8, 2011 BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ... Product Development of BioMarin, will present a company update at ... June 15, 2011 at 10:00 a.m. CT.   ... conference call via the investor section of the BioMarin website, ...
Cached Medicine Technology:National Comprehensive Cancer Network Guidelines Available in Elekta's MOSAIQ EMR 2BioMarin to Present at the William Blair Growth Stock Conference 2
(Date:7/31/2014)... NY (PRWEB) July 31, 2014 NEWwoodworks, ... , is expanding their brand presence with a website ... over 20 years, NEWwoodworks has specialized in handcrafted cabinetry, ... interior furnishings. NEWwoodworks has earned a reputation for taking ... dare take on. They commonly craft with reclaimed wood, ...
(Date:7/31/2014)... Ticket Down is a dependable source for authentic ... Sun Life Stadium in Miami on Monday, August 4th. ... and diehard soccer fans from the Miami, Florida area are ... Cup final in person at Sun Life Stadium. ... split into two groups where they will then play each ...
(Date:7/31/2014)... 2014 The VitaSleep FDA cleared ... and provide an easier breathing capacity by slightly adjusting ... that people can breathe easier and helps reduce or ... so that it can meet the needs of each ... often shared by actual customer reviews. Johathan R. ...
(Date:7/31/2014)... Denver, Colorado (PRWEB) July 31, 2014 ... commonly doctors recommend pain killers for this health problem. ... reveals that this new program was created by Peter ... purpose to help sufferers from all over the world ... , If people wish to view pros and ...
(Date:7/31/2014)... 31, 2014 A program for anyone ... to the University of Colorado Anschutz Health and ... loss boot camp and transformation program. , “Extreme ... and Eyeworks USA, is an evidenced-based program inspired by ... by Eyeworks USA. This season, the show has participants ...
Breaking Medicine News(10 mins):Health News:NEWwoodworks Fine Woodworking Group Launches New Website 2Health News:NEWwoodworks Fine Woodworking Group Launches New Website 3Health News:Guinness International Champions Cup Finals Tickets in Miami, FL Available at Ticket Down 2Health News:Guinness International Champions Cup Finals Tickets in Miami, FL Available at Ticket Down 3Health News:New Dental Device Reviews to Stop Snoring by VitalSleep 2Health News:Neuropathy Miracle Review Reveals Peter Bansby's Unique Cure Method 2Health News:"Extreme Weight Loss: Destination Boot Camp" Comes to Colorado - The CU Anschutz Health and Wellness Center Begins Transformational Program 2Health News:"Extreme Weight Loss: Destination Boot Camp" Comes to Colorado - The CU Anschutz Health and Wellness Center Begins Transformational Program 3
... Blue branded dental plan,to central Pennsylvania (Lehigh Valley) ... BlueCross announced,today that it is acquiring Dominion Dental ... The move by the region,s,leading health insurer adds ... the Mid-Atlantic Region., "Helping to improve the ...
... Nov. 4 Hospira, Inc.,(NYSE: HSP ), ... announced that Christopher B. Begley, chairman and chief,executive ... Finance,and chief financial officer, will make a formal ... Conference on Wednesday, Nov. 12, 2008, in,Phoenix., ...
... PH ), the global leader in motion ... the purchase of Matrx nitrous oxide,delivery systems from ... to expand its geographic market space for dental ... American base of operations. The,product line will be ...
... Nov. 4 Allied Minds funds research to ... dermal fillers.,Allied Minds, a seed investment firm specializing ... research with Lawrence Berkeley National,Laboratory through creation of ... Eva Turley and Mina Bissell will develop a,technology ...
... of Minnesota Leverages Market Dynamics With New, Plan Offering ... ... NASHVILLE, Tenn., Nov. 4 ,HealthLeaders-InterStudy, a leading provider of managed ... the,national trend of moving from fully insured to self-insured health plans.,According ...
... Sold by A Uniquely-Trained Sales ... ... today announced that SANCUSO(R) (Granisetron Transdermal System),is now available by prescription for ... approved by,the U.S. Food and Drug Administration (F.D.A.) in September 2008 as ...
Cached Medicine News:Health News:Capital BlueCross Acquires Dominion Dental 2Health News:Parker Acquires Medical Gas Delivery Product Line, Expanding Its Dental Equipment Offering 2Health News:Parker Acquires Medical Gas Delivery Product Line, Expanding Its Dental Equipment Offering 3Health News:New Skin Rejuvenation Discovery Receives Commercial Backing 2Health News:Minnesota Employers Buck National Trend and Largely Remain Fully-Insured 2Health News:SANCUSO(R), the First and Only Patch for Preventing Nausea and Vomiting in Chemotherapy Patients, Now Available 2Health News:SANCUSO(R), the First and Only Patch for Preventing Nausea and Vomiting in Chemotherapy Patients, Now Available 3
Retractable, straight double Lancet Blade, 15 Degree Angle , available in variations; Titanium handle...
10mm Tip to Bend, 0.3mm Y Tip; In Titanium....
Bend with "H" Shaped Tip, LEFT; in Titanium....
Bend with "H" Shaped Tip, Right; Stainless Steel....
Medicine Products: